We are living through a genuine inflection point in obesity care. GLP-1-based therapies have reshaped clinical practice, cardiometabolic guidelines are evolving in real time, and major health systems are reorganizing care around integrated cardiometabolic models. Programs like Cleveland Clinic’s CardioMetabolic Health Center reflect this shift — bringing cardiology, endocrinology, obesity medicine, and prevention into a single coordinated framework.
But as we redesign obesity care, one system remains conspicuously absent from the conversation:
The venous system.
The symptoms we normalize — and shouldn’t
Patients with obesity frequently describe leg heaviness, tightness, swelling, aching, or early skin changes. Too often, these complaints are dismissed as “dependent edema,” attributed to body habitus, or vaguely labeled as “circulation issues.” In reality, many of these symptoms represent early manifestations of phlebesity — obesity-related venous disease — a condition that remains under-recognized despite being common and clinically consequential.
Why venous disease hides in plain sight
Venous disease in patients with obesity rarely presents the way it does in textbooks.
Clinical blind spots include:
- Edema written off as positional or “expected”
- Gaiter-area hyperpigmentation mislabeled as eczema or diabetic skin disease
- Duplex ultrasound studies limited by habitus and interpreted as “normal”
- Reflux underestimated because visualization is incomplete
Obesity alters venous hemodynamics by increasing intra-abdominal pressure, impairing calf-pump function, promoting inflammation, and accelerating venous hypertension — often before classic reflux patterns appear. A hemodynamic study showed clearly that simply lifting the abdominal pannus immediately improved venous diameter and flow in the great saphenous vein and common femoral veins.
Population data show the same pattern: Higher BMI correlates with more advanced chronic venous insufficiency (CVI), even when adjusting for diabetes, hypertension, and other metabolic disease..
The GLP-1 paradox
GLP-1 receptor agonists have transformed obesity and cardiometabolic care. They improve weight, glycemia, blood pressure, inflammatory markers, and cardiovascular risk. The American College of Cardiology (ACC) recently issued guidance that GLP-1-based obesity treatment can be part of cardiovascular prevention.
These therapies are a major step forward.
But here is the paradox: None of them reverse established venous disease.
Even substantial weight loss does not reliably:
- Regenerate venous valves
- Reverse established reflux
- Resolve lipodermatosclerosis
- Eliminate ulcer risk (CEAP 4–6)
Emerging evidence suggests GLP-1 therapy may even reduce VTE risk, but this does not reverse CVI.
This creates a false reassurance loop:
The labs improve.
The scale improves.
The legs don’t.
And because venous disease is not emphasized in obesity or cardiometabolic guidelines, clinicians often stop looking.
Why cardiometabolic clinics should care about veins
Modern cardiometabolic programs — Cleveland Clinic, Baptist Health, UCLA, WVU, and others — are designed to manage overlapping cardiometabolic risks: diabetes, ASCVD, obesity, heart failure.
Yet chronic venous disease is rarely included as part of the routine assessment, despite:
- Venous pain limiting mobility
- Mobility limitations undermining weight-loss plans
- Edema and skin changes increasing ulcer risk
- Venous hypertension worsening with central adiposity
From a systems perspective, this is not a small oversight — it is a structural blind spot.
If a patient’s legs hurt every time they stand, “walk 30 minutes a day” is not a lifestyle plan — it’s a setup for failure.
Outcomes data show diagnosis is late — not wrong
U.S. vascular outcomes research consistently shows that patients with higher BMI have worse results after venous procedures, especially above BMI 35 kg/m². This does not mean treatments fail in patients with obesity. More often, it means that the venous disease is more advanced by the time we finally diagnose it. We fully accept that obesity accelerates heart failure, fatty liver disease, sleep apnea, and diabetes. There is no physiologic justification for excluding the venous system from that same logic.
Practical changes — without turning visits into vascular consults
A few deliberate habits can dramatically improve recognition:
- Take leg heaviness, tightness, and swelling seriously in patients with obesity.
- Reassess venous symptoms after GLP-1 weight loss — plateaus matter.
- Treat “limited” ultrasounds as incomplete, not normal.
- Examine the gaiter area for hyperpigmentation or induration.
- Add a simple venous symptom checkbox to cardiometabolic intake templates.
These adjustments are small yet clinically meaningful.
The bottom line
Obesity care has evolved. Cardiometabolic care has evolved. Our pharmacology has evolved. Our attention to the venous system has not. “Phlebesity” is common, under-diagnosed, and functionally limiting. If cardiometabolic care is meant to be comprehensive, venous disease cannot remain an afterthought. For many patients, the first alert that their physiology is under strain is not chest pain or dyspnea. It’s something much quieter: “My legs feel heavy every day.”
In the GLP-1 era, that complaint deserves to be taken seriously.
Shafi S. Rana, MD, MBA, is a board-certified family medicine physician in New York. His clinical work spans obesity and vascular medicine, with a focus on cardiometabolic disease and longitudinal care. He integrates medical expertise with experience in finance, physician leadership, and health system operations to strengthen patient outcomes and organizational performance. His interests include the thoughtful integration of AI and emerging technologies to improve access, quality, and long-term value in health care. He is a 2025–2026 Doximity Op-Med Fellow.
Image by Alphavector / Shutterstock
